-----BEGIN PRIVACY-ENHANCED MESSAGE-----
Proc-Type: 2001,MIC-CLEAR
Originator-Name: webmaster@www.sec.gov
Originator-Key-Asymmetric:
MFgwCgYEVQgBAQICAf8DSgAwRwJAW2sNKK9AVtBzYZmr6aGjlWyK3XmZv3dTINen
TWSM7vrzLADbmYQaionwg5sDW3P6oaM5D3tdezXMm7z1T+B+twIDAQAB
MIC-Info: RSA-MD5,RSA,
QZgSFnnDB3lszRVVevVsZURvKdZJniiAdSPbXrdS1XZ4p6MzOhwFfpUe6PzjeMOD
ntruP2sgIgumi9giq9sB+g==
0001193125-04-019966.txt : 20040212
0001193125-04-019966.hdr.sgml : 20040212
20040211175600
ACCESSION NUMBER: 0001193125-04-019966
CONFORMED SUBMISSION TYPE: 8-K
PUBLIC DOCUMENT COUNT: 3
CONFORMED PERIOD OF REPORT: 20040211
ITEM INFORMATION: Other events
ITEM INFORMATION: Financial statements and exhibits
FILED AS OF DATE: 20040212
FILER:
COMPANY DATA:
COMPANY CONFORMED NAME: ALEXION PHARMACEUTICALS INC
CENTRAL INDEX KEY: 0000899866
STANDARD INDUSTRIAL CLASSIFICATION: PHARMACEUTICAL PREPARATIONS [2834]
IRS NUMBER: 133648318
STATE OF INCORPORATION: DE
FISCAL YEAR END: 0731
FILING VALUES:
FORM TYPE: 8-K
SEC ACT: 1934 Act
SEC FILE NUMBER: 000-27756
FILM NUMBER: 04587617
BUSINESS ADDRESS:
STREET 1: 352 KNOTTER DRIVE
CITY: CHESHIRE
STATE: CT
ZIP: 06511
BUSINESS PHONE: 2037761790
MAIL ADDRESS:
STREET 1: 352 KNOTTER DRIVE
CITY: CHESHIRE
STATE: CT
ZIP: 06511
8-K
1
d8k.htm
FORM 8-K
Form 8-K
SECURITIES AND EXCHANGE COMMISSION
WASHINGTON, D.C. 20549
FORM 8-K
CURRENT REPORT
PURSUANT TO SECTION 13 OR 15(d) OF THE
SECURITIES EXCHANGE ACT OF 1934
Date of Report (Date of earliest event reported) February 11, 2004
ALEXION PHARMACEUTICALS, INC.
(Exact Name of Registrant as Specified in its Charter)
|
|
|
|
|
Delaware |
|
0-27756 |
|
13-3648318 |
(State or Other Jurisdiction of Incorporation) |
|
(Commission File Number) |
|
(IRS Employer Identification No.) |
|
|
|
352 Knotter Drive, Cheshire, CT |
|
06410 |
(Address of Principal Executive Offices) |
|
(Zip Code) |
Registrants telephone number, including area code: (203) 272-2596
Not Applicable
(Former Name or Former Address, if Changed Since Last Report)
Item 5. Other Events and Regulation FD Disclosure
On February 11, 2004, the Company announced the appointment of Carsten Boess
as Vice President and Chief Financial Officer, a newly created position. A copy of the press release issued by the Company relating thereto is filed herewith as Exhibit 99.1.
Item 7. Financial Statements and
Exhibits.
|
99.1 |
Press Release dated February 11, 2004. |
2
SIGNATURES
Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the
undersigned hereunto duly authorized.
|
|
|
|
|
|
|
ALEXION PHARMACEUTICALS, INC. |
|
|
|
Date: February 11, 2004 |
|
By: |
|
/S/ DAVID W. KEISER |
|
|
|
|
|
|
|
Name: |
|
David W. Keiser |
|
|
Title: |
|
President and Chief Operating Officer |
3
EX-99.1
3
dex991.htm
PRESS RELEASE DATED FEBRUARY 11, 2004
Press Release dated February 11, 2004
Exhibit 99.1
For Immediate Release:
|
|
|
|
|
|
|
Contacts: |
|
Alexion Pharmaceuticals, Inc. David Keiser President and Chief Operating Officer 203-272-2596 |
|
Euro RSCG Life NRP Ernie Knewitz (Media) (212) 845-4253 |
|
Rx Communications Rhonda Chiger (Investor) 917-322-2569 |
ALEXION PHARMACEUTICALS APPOINTS CARSTEN BOESS
VICE PRESIDENT AND CHIEF
FINANCIAL OFFICER
Cheshire, Conn, February 11, 2004 Alexion Pharmaceuticals, Inc. (Nasdaq: ALXN) today announced the appointment of Carsten Boess as Vice President and Chief Financial Officer, a newly created position. Mr. Boess
joins Alexion from Novo Nordisk International Operations where he most recently held the position of Vice President of Finance and also served as Chairman of Novo Nordisks International Operations Finance Board. Reporting to David Keiser, Mr.
Boess will be responsible for all areas of accounting, finance, and administration, from operational and strategic viewpoints.
We are very pleased to have Carsten join Alexions management team, said David Keiser, President and Chief Operating Officer. His extensive
experience, in the U.S. and abroad, in all areas of accounting and finance within the pharmaceutical industry will be a tremendous asset to our organization as we move into the next phases of Alexions development and prepare for operating in a
product revenue generating environment.
Mr. Boess began his career at
Novo Nordisk in 1991 as Corporate Controller. Subsequently he took on assignments with increasing responsibility including, at one time, Manager Investor Relations and Finance for Novo Nordisk North America, based in New York, as well as Senior
Director Finance and IT of Novozymes North American operations. Mr. Boess holds Bachelors and Masters degrees in economics and finance from the University of Odense, Denmark.
(more)
- Page 2 -
Alexion is engaged in the discovery and development of therapeutic products aimed at treating
patients with a wide array of severe disease states, including cardiovascular and autoimmune disorders, inflammation and cancer. Alexions two lead product candidates, pexelizumab and eculizumab, are currently undergoing evaluation in several
clinical development programs. Alexion has completed a Phase III clinical study with pexelizumab in CABG patients undergoing cardiopulmonary bypass, and two large Phase II studies with pexelizumab in acute myocardial infarction patients. The Phase
III trial and Phase II trials were conducted in collaboration with Procter & Gamble Pharmaceuticals. In addition, eculizumab has completed Phase II clinical trials in rheumatoid arthritis and membranous nephritis, and has completed pilot
programs for the treatment of paroxysmal nocturnal hemoglobinuria and dermatomyositis. Alexion is engaged in discovering and developing a pipeline of additional antibody therapeutics targeting severe unmet medical needs, through its wholly owned
subsidiary, Alexion Antibody Technologies, Inc. This press release and further information about Alexion Pharmaceuticals, Inc. can be found on the World Wide Web at www.alexionpharm.com.
This news release contains forward-looking statements. Such statements are subject to factors that may cause Alexions results and
plans to differ from those expected, including the results of pre-clinical or clinical studies (including termination or delay in clinical programs), the need for additional research and testing, delays in arranging satisfactory manufacturing
capability, inability to acquire funding on timely and satisfactory terms, delays in developing or adverse changes in commercial relationships, the possibility that results of earlier clinical trials are not predictive of safety and efficacy results
in later clinical trials, dependence on Procter & Gamble Pharmaceuticals for development and commercialization of pexelizumab, the risk that third parties wont agree to license any necessary intellectual property to us on reasonable terms,
and a variety of other risks set forth from time to time in Alexions filings with the Securities and Exchange Commission, including but not limited to the risks discussed in Alexions Annual Report on Form 10-K for the year ended July 31,
2003 and in our other filings with the Securities and Exchange Commission. P&GP retains the development rights and the termination rights discussed in Alexions Form 10-K referred to above. Alexion does not intend to update any of these
forward-looking statements to reflect events or circumstances after the date hereof, except when a duty arises under law.
# # #
2
GRAPHIC
4
g32341image002.jpg
GRAPHIC
begin 644 g32341image002.jpg
M_]C_X``02D9)1@`!`0$`8`!@``#__@`<4V]F='=AT[NU=[E!U?62UL>CM,9ENU9YDTC#^`:1O&>HXWD]0]9"V+1
M>CZ/1UF;1P8DJ9,.J:C&^1W@.H(.]IW3U!IBSQ6RWQXC8,O>?2D=UN=ZRM::^T.'0R,.R90-X:3V]A^0[ENZ(-/T!KEFJJ)])6L%->*/S:F
MG(V2[!QM`'U\1U'Y%N"G?*!HZL;6,UAI?,-XI//ECC'XPT<3CK.-Q'QANXX6
MPZ+UC1ZQLXJH<1546&U-/G?&[_5IZCX(-C1$0$1$!$1`1$0$1$!$1`1$0$1$
M!$1`1$0$1$!$1`1$0$1$!$1`1$0$1$!$1`1$0$1$!$1`1$0$1$!$1`1$0$1$
M!$1`1$0$1$'_T;,B(@(B("(B`B(@(B("(B`B(@(B("(B`B(@(B("(B`M+Y0=
MZ[#*>)@VC'G=M$=O8.L^H%>EK36%'HZS.JYL2U,F6TU/G?(
M[P'65KO)YI"L-9+K#4F9+M79?%&\?@&GKQU'&X#J&[M0>ER?:'&F*-]?<2*B
M]5OGU,SCM%F=^P#[=Y/6?D6Y(B`B(@*6ZST]7Z.O7W<:7CPT'-PHQZ#FGTG8
M'4>OL._M526'-:]I:X!S7#!!&00@\O3FH:#4]GBN=ODRQXP]A]*-W6T^L+U5
M([I0UG)/J@WVV1/GT]7OV:JG;_P23P'L^*?:WL*J5NN-)=K?#7T,S9J>=HL(.TB(@(B(/D^JIXIXX)*B)DLGH1N>`YWL'6N+:VD?,^%M5"Z6,$O8)`7-
M]HZEI.KVTWPVUD-,_P"$99Z9VRZ!SW53&/!`BD&Z/9\XN/BO*#J>C%QA?'+7
MP/CJ7W%C*#F:B`F3::S;&2[:)QC)W#/!!3:>JIZN+G::>.>/.-N-X<,^T+AY
M?1D0D54.*@[,)YP??#V-[>!X+7=%"FF^$:V&2(25,C#)34\+XXH,-P`W:`VC
M@;W`#.[=N6L62FN5HM\=;60R3OJK?+#;Y&0D.H)&AY#,;\%_':[1CAA!45Q<
M]C?24SUE965=!)))Y1ES]MS/1#<;AV!!L]%=+?<@\T%=3589Z7,2M?L^W!
MW+[MFB?*^)LC'21XVV!P);GAD=65.ZR7RJ-M?INEGIY*2TU#:BHBI71;3RUN
MPP9`+G!P)X;OE7;G-UL534U,$EPK8;=Y-(]K@7R53'-D#QN'G$%S3CJP@WQ%
M-2[4E-?*."JK*SRB,T_--VGEDP=YTV6ANRX`EPRYPV0UORT:HF934\D\F=B)
MA>[9&3@#.X=:#GM`N+V35(W!
M\CGXP[:).,$[6TNBV*^V>RQT])67&6.:WTDL[I7'-."[9DV"&DLPW&X`X`SA
M!35\Q40EDCQ-&61$A[MH8:1QSV84RJZR\LM=$_X0N#XV.F-.(W2-?48<-@>[B`'M`<#E=HTMSI9ZNO@FN##55]7&^EQF(,,+G`[...T!YWR(**Q[9&->
MQP5TSZ5T@>7/@:X#)GD
MF.(V2RM:7^P$[U\Y;[9X)G0S7:BCE8=ES'U#`YI[""5JM=);K=?+_P##EMDJ
MY*\,\C;S!D\HC$8;S3"`<';VMV[TLKNOL],_4EB>^T11M\BFYUKHQ)L.Q'@.
M=C>1O&3QP4&UID;6SD9`SA<99&00OE?D,C:7.P,[AZE%;7K*_CE)EOU3:KBV
MV59%,^(T[\1PY\QW#B#O/M<@MJ^,=732F41U$3S"<2AKP>;/8[L^59G$CJ:0
M0D"0L.P>PXW*5/HWS6J"*V44L,M-;V17C:I79<_GHRX.&[G#@2N('$'UH*I'
M54\M-Y3'41/@P3SK7@MP.)SP7,RQ@L!D;F3T!GTNO=VJ7UU+=*S25QI;;;V5
M-K,LTCYH&^3&J`C&R1'CAM9SLXVMCUE;*^AD?J73-RDI)8JDP3,F'.%[(OO6
MX?Q1OZ\#*#:8ZF"662*.:-\D1`D8UP)9[1U+ZJ?:2@V;Q:HX*9\-;2TU0V\/
M,1:7/R
M"#P(/L7":>*FA=-/*R*-N]SWN#6CVDJ5\D&H+HRHJ;'>*>L^_O=403S1.`VS
MO>TDCK](?*MXUS!)4Z2JH88Q)(Y\.RUS"\?A6<0.([4'KPW"AJ6-D@K*>5CG
M[`YN!C/IM`#L]>%V]`UESJ:BI%773U<9@C?)SSG/YJ
MI3*H;2W&NN#+0'4U;`*SFR6.\JK9'-<'9=@`,&3LC))V6\%]V-L9?5U$
M%(&69K*5K2Z!WD[*IK9/.E:,9:,L#O7C/!!2FN:]HU:1:I*FGT*^&II'BU\S5&:HIWN9)L[;\X16^@J'R&!L%KBA+XX)-[&%V0`YQ+O.('!ORH*)Y3!AAY^/$AP
MSSQYQ[!VKG)(R)ADD>UC&\7..`%,K]:[+:/)]/@Q13>0M8ZMJ6G8IP7DN?$T
M#\*YQ)W8QAO5N7MZJKA#!3F\6^.2&.K`HFNGVH9_,=Y\PV?-:!OQOR<(/__2
ML3IX6;.W*QNUZ.7`9]BR)8S(8P]I>T9+<[P/8I7/#2T%-0RMK*&XR0T0\DII
MJ%TC*EYF>2R$D[L9#<;R`&YW+Z3QU;[W506N)CKE'+72RS1[3:G#HW[#7@CT
M0XL#3D@X:0!O05%DC),[#VNP<'!S@]BY+2=`&%M151TT=+)&*:#;J*2%T31)
MAP,;@2:ZN!A@V&DE@QYS]W8#N]9"#<5\Y9H
MH&[M"Y(]3R7:P?!%:)!66YH:UTC2#)%\4[^L<#\G:O6US2R
MULEA@ABII7NN6YM7$9(OP,OI-''QP@VB*:*=FW%(R1O#:8X$+FIE>;M7Z=KX
M***>"@?2MBEDIZ.-D-/-MR^>0P@N>-GB00&XSE>YI^\UU;JF>EGKWR6]G/&A
MDYH#RS#AMY=U\V?-&,9!SO0;AD;6SD9XX3(.<$;N/J4YK9+=4ZSGCI*R*.X0
M5FV:BIF`F<_F\"GA;Q+-XR3NWGB>'0MWP.:1C1-*RE^#H?ADL+B!4SGJ054$$9!R"F5H>EJVKIK'51T],R:A-5.7UU',&P4[,`[4+79+FC)W
M#/G`KRK*=-U%MN=>XTT]M@H6O?0^4"2:^9F6$;\M;N`&>I=_6];6NMLU-/0BFH_*H&"KEG
M',R-+AM'4@W)%,Z>)\ND:&9E=*V.COC6-;2R_N:9IJ&@!N=YC&<
M#?Q!6*^29NNGQT[VRW!]Q`%2VH(DA@YK)C,/$M'I9`V3D;\H*:BG7)Y,Y][=
M'3-;S#;N=4Q:2TU/7$M-2_P"]TL9/
MI2'A\@XGV(-B13GDAUBZ]VF2SU]0Z6X47G->]V72Q$[CGK()P?D6T:LO-58+
M?#<86AT#)MB=NP7$AS2UF.S[X6?(2@]Y%/6ZTOD5`^MJ(H0VBF;05;6QD[52
M6.&1_P!/.&(>QQ61K2^BW&MDIX!S4PMTK-@[ZS8(W;_1YW9;["@H*+3[;K&:
M:RW"NKY*:FDI8W,8QS79=+$P<\=G.7-#SC=U!>/'J2ON-;2TM361!])=(ASK
M2UN6OIY78>UKB,`CAGJW[T%(1:#;]9WBZPTS830P35-:RC&U&]VRWFGO,P!(
M)#]G+!PQQ)7H?==.-)0UQ=1MN$DHA?M.Q',8N=<,Y#,C/'U90;;:-KS7#XV\X)&%G[J-05EQBBI1;X(JBL?2
MQMFC>Y\9;!SI<[#AD\6XW=J#>$7G:?N3[O8*&XRL:R2IA:][6>B"1OQZD0=7
M5VIHM)6)]UFIGU#&R-9S;'!I\XXZUH?3S;^XJKZ9J]OEF_W?3_I$7^9?GK>N
MR&+Y^_B_46KIZMW<55],U;72:\IW:0DU/'S\%(>
M3W1<-Y?+?KX1!8J#+Y7R;A,X;]G\T=?S>S;*"EJN5G4PK:F)]/I>V/V((/1Y
MXCJP.L]?8-W:LYO(_GVOD\?;2MJGU9=9-?:NU[Y=J3SAV%CL+2>6&]P4M#;]+13QTL=6]CJEV/-
MB@:0!N'5G?C_`*5YW)E?;7:=;7'3MMKA4VJN/.44AR,/`WM.<;R,CU[(7.K>
MF5NJ)*Y]`VY:<=5QL#WP!DI>UIZR-O.%V-C6F?QBQ?03?;6OVK_?G>]W\%Q?
ML+5JGE)U;427*>A<6QT]1(R&)EM,L>RTX\Z7/FG'J04G8UG_`#BQ_03?;0QZ
MR/\`S5D'_CR_;7BZJU3>K=HFV:FHGTT!Q??D[
MU#=M54-==J^:F%,Z=T=-2Q-\Z(#^.>L[Q\V>M!VZ&KU)6%\
M,,CP'#B,A_%=CF-99_'[-]5E^VM4TCJ*2BY+KS>8:.C@EI)YRR."+887`-P2
M,[UYL^K-=VO3]KU)5W2UU%'6RQ@TK(
/`<%U;#-7ZQDU%H_5XIZI]"6`3T[-G!.<$>
ML8!!0;O=+G)1V:2Y4-(ZY;+!(V*!X!D;QRT\#NW^M3KIXMG<=9]*Q<=(WRNT
M!J#[B]22YHI'9M]8[BE?+J6SP_>G':K8T#_*`
M=G;\_:MH?/CZ]KZ3UZ73Q;1_`=7]*Q8Z>;;U6*K^E:HKGL6,KMS1I?JU=/-N
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MUAO@HR/:LCVIGCX7ZLO3U2_T?FS^D-\%P/+K1&43?:7KT_-G](;X+'3S3_T?F^L#P4;^5%<\7$OU9!R\TW]'YOK+
M?!.GJF_H_-]8;X*-+.],\?"_5DZ>:;?_`/'YOK(\$Z>:;/[WYOK`\%&T3/%P
MOU9>GFES^]^?ZPWP6#R\T_5IZ;ZRWP4<";TSQ\+]6+IY@_H]+]9'@AY>8,[M
M/RX_21X*.(F>/A?JQGEZ@ZM/R_+4CP3IZI_Z/S?6!X*-Y3/J3/'POU__T^WT
M\T_]'YOK`\$'+S3=>GYOK#?!1O*QGU+ZN>+CQ^UFZ>:79W:?GS^D-\%CIYIL
M?O?FS^D-\%&\^I%<\7"_5EZ>J7N"?ZPWP0GFA[AJ?IV^"BV5G*9HN%^K1T\4'78:KZ9O@L]/%N/\!5?TS5
M%D3-%POU:>G>V$@FQ5>[A]]8G3O;`218JO)Z^=8HKO62F:/A?JU#EWM@X6*K
M&=^Z1B'EWM1XV.L/]MBBB)FCX7ZM8Y=K2-XL58/8]BST[VD\;)6^^SQ430J9
MH^%^K6>76SN.38ZPG&,ES."R.76S#&+)6C'##F;O[U$EDIFCX7ZMG3G8]K:-
MCK-KCG+/%9'+I8QM#X%K1M>EZ&_V[U$L[T3-&M^K<.72QM;LBS5P;V#8Q^M8
M;RX:>:#LV2M&1OPV/?\`WJ)9WH2<)FCX7ZN!Y=+"[1_+=I:0#;MMQ=C
MAM0QG]I0I,J98RUT;RV:58[:9;;BPCK$$8_:7-W+AI=[=EU!L_.5#TSA,T9?JZ#EFT<'MD^"ZX/;@-=Y-'D8!`P=KJR?G7'IAT40X&TUF',
M+'#R2/>TG)!\[ADDX4-)3*9HR_5O/*SH-T,$#K+4F*F.U"PT<>S&>UHVMR^P
MY8]&!XD%NK=L/,@=Y*S.T1@NSM<<;LJ%+(*9HRUYBY:=(4\388J6OBC8,-8V
MG:`!ZAM(H(_CQZD5RQI?K],\HFGJ[4^DY+;;N:\H=,QXYUVR,`[]ZF%NY$]0
M/N,+;G-2046WF>2*7:<&CC@8X]2O"F>OM3UU[NK=#:8.W55!V:V=IW1-^,W(
MX;O2/R<2N#XF^OCYKQZIX]QPG#X@!N\UIW
M=7]Y7SN-SL]PK:&M^X'4%)/0R![F12./$EH/6K2B
M6)-<[O;[L+;'5Z#U)Y/:RTTU.V/$8QC&6]>X8W^OM7UM.H*>QW2OK[=H74D3
MZ]VU/$&?>R[.>':JHB"4VV^4UJL539(.3_`%"^BJG/=-'*S:VML8=O
M7ATUML5-50S-Y/\`5,O,OVV12/<69SD;E;^=CY[F><;SNSM;&?.QPSCL7-!,
M:C4SJK4=+?9=`ZB-=21.BB(9AH:
M&G.R<9P>PX(6GA_NFHV7"W.YB\T/G4\K3LE^-^P3U;]X/4?:@U&_::R5U-3T4AVFPS;68R>(!`X=B\[H*OW>MO^9_@M_Y/-;_=+1OM]R',7FB\
MVHB<-DR`;MH#V[B.H^T+=%OY^1)Y_4I#.@J_=ZV_YG^"=!-][UM_S/\`!7-$
MT2=*0WH)OF/RM0>Z_P`$Z";YN_VO08_-?X*Y(FB3I2''D(O??%![K_!!R$7K
MKO%![C_!7%$T2=*0[H)O?5=Z#W7^"=!-[W_[7H/=?X*XHKHDZ4AW03>^]Z#W
M7^"ST$7K/Y8H/<>K@BFB3I2'#D(O6-]XH`>S8?X+(Y"+UC?>*'/9L/\`!7!$
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M=!-\[WM_NO\`!7%%-$G2D.Z";YWM;_=?X)T%7SO:W_,_P5Q173)TKQ#>@J^]
M[6_YG^"ST%7WO:W_`#/\%<433)TKQ#>@J^][6[YG^"=!5^[VMWS/\%@J_=[6[YG^"=!=_[UMW^)X*Y(FF3I7B&=!5_[UMW^)X)T%7[O6W?XG@K
MFB:9.E>(9T%7_O2V_P")]E8/(7J`#==+:?ED^RKHB:9.E>(4>0O4._%SMOSR
M?96.@S47>%MX?QG_`&5=D33)TKQ"#R&:C'"X6T_VG_96#R&ZDZJZVG^V_P"R
MKPBNF0I!CR':F'"MMI_MO^RL=!^I\']V6X_]Q_V5>D35(4@G0AJC^1O66/Q:D/_DA8Z'=9#<*2F/\`Y+5^B$35(4_.W0]K/^94_P!9:N)Y(-:`
M$_!\!QV5+/%?HM$U??\`A3\Y'DBUH/X,C/LJ6>*XGDEUJTX^"F'V5,?BOT>B
M:OOGA3\W'DIUJ!^1\^RHC^TN/17K7N1WUB/[2_2:*Z_OGA3\U]%NM1_`;_IX
M_M)T7ZU'\!2?3Q?:7Z41-?WSPI^:7KY^I=_0.B8=(VLNG(GNE5YU5.=YSQV0>P?
MWG>NS%^_.3V_L+8UR*FMCM=77Z8HI&6RA@A@EDG-<),S/#7OW!H:,$\-[CNR
MOK2W2X6/3EN8+F][*BT0R1YBCQ`[:B8-D[@&X?Q=G&,^I;O0?DAOYKOUE=6;
M\2'Z`[]34&N4-UO57S="ZXOB:ZYMIVU+713/=&8'/<`\-V20X8SLY'8N=377
M^FBN,DEYVI;;/34^&4[!'(7B,.<0_)]-_6C_(5Z::YM0YX.T2W&TX9&,,(6QW[\6=^EQ_J"Y5'XW:/:?U(4U
MEFH+W+C@KWU<
M?E=-27%D=1(1(T;#HPUSBP8=ZR!O[%[.B[G/5S5E+45\U8^-DM;5HO5U+K"RMK(F\S4QX;4P'C&[U=H/45[L/X%J^%'Z;_`_`%0=
MM$1`1$0$1$!$1`1$0$1$'__5LR(B`B(@(B("(B`B(@(B("(B`B(@(B("(B`B
M(@(B("(B`B(@(B("(B`B(@(B("(B`B(@(B("(B`B(@(B("(B`B(@(B("(B`B
&(@(B(/_9
`
end
-----END PRIVACY-ENHANCED MESSAGE-----